SRNE - Sorrento Therapeutics, Inc.

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Sorrento rises as FDA clears Phase 1 trial for COVID-19 therapeutic
• Sorrento Therapeutics subsidiary Scilex to acquire Ancora Medical
• MFGP, SRNE and OPEN among pre market losers
• Sorrento unit Scilex gets license to commercialize Romeg's gout treatment Gloperba
• Inovio Pharma, Bionano Genomics among health care stocks to join Russell Microcap Index; Tonix Pharma, iBio to leave
• Sorrento's Scilex repurchases $41.4M notes ahead of going public with SPAC Vickers Vantage
• Sorrento' unit Scilex begins dosing in mid-stage study of SP-103 for lower back pain
• Sorrento stock rises after FDA gives nod to begin phase 2 study of abivertinib to treat prostate cancer
• Scilex, part of Sorrento Therapeutics names new CFO
• Sorrento subsidiary Scilex expands distribution network to national, regional wholesalers
• Sorrento gets FDA nod to start early-stage trial for intravenous COVID-19 therapy
• Sorrento granted FDA clearance to start late-stage trial for COVID-19 therapy
• Morgan Stanley projects about a third of biotechs will need financing in 2022
• Sorrento subsidiary Scilex to enter deal for $5 billion equity financing
• Sorrento subsidiary Scilex to go public in SPAC merger with Vickers Vantage
• Sorrento Therapeutics sciatica pain treatment meets primary endpoint in phase 3 trial
• Sorrento granted FDA nod to start clinical trial for intranasal COVID-19 therapy
• Sorrento' COVISHIELD shows neutralizing activity vs Omicron subvariants
• Sorrento acquires a majority stake in FortuneBio to meet demand for rapid COVID-19 test
• Sorrento rises 7% as STI-1558 neutralizes omicron in cell-based tests